JP2023539625A5 - - Google Patents

Info

Publication number
JP2023539625A5
JP2023539625A5 JP2023513704A JP2023513704A JP2023539625A5 JP 2023539625 A5 JP2023539625 A5 JP 2023539625A5 JP 2023513704 A JP2023513704 A JP 2023513704A JP 2023513704 A JP2023513704 A JP 2023513704A JP 2023539625 A5 JP2023539625 A5 JP 2023539625A5
Authority
JP
Japan
Prior art keywords
compound
free base
composition
combination
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047826 external-priority patent/WO2022047083A1/en
Publication of JP2023539625A publication Critical patent/JP2023539625A/ja
Publication of JP2023539625A5 publication Critical patent/JP2023539625A5/ja
Priority to JP2026028376A priority Critical patent/JP2026083121A/ja
Pending legal-status Critical Current

Links

JP2023513704A 2020-08-26 2021-08-26 Tlrアゴニストによるがんの処置 Pending JP2023539625A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026028376A JP2026083121A (ja) 2020-08-26 2026-02-25 Tlrアゴニストによるがんの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070376P 2020-08-26 2020-08-26
US63/070,376 2020-08-26
PCT/US2021/047826 WO2022047083A1 (en) 2020-08-26 2021-08-26 Cancer treatment with tlr agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026028376A Division JP2026083121A (ja) 2020-08-26 2026-02-25 Tlrアゴニストによるがんの処置

Publications (2)

Publication Number Publication Date
JP2023539625A JP2023539625A (ja) 2023-09-15
JP2023539625A5 true JP2023539625A5 (cg-RX-API-DMAC7.html) 2024-08-30

Family

ID=80355767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513704A Pending JP2023539625A (ja) 2020-08-26 2021-08-26 Tlrアゴニストによるがんの処置
JP2026028376A Pending JP2026083121A (ja) 2020-08-26 2026-02-25 Tlrアゴニストによるがんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026028376A Pending JP2026083121A (ja) 2020-08-26 2026-02-25 Tlrアゴニストによるがんの処置

Country Status (8)

Country Link
US (1) US20230346775A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203962A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023539625A (cg-RX-API-DMAC7.html)
KR (1) KR20230057409A (cg-RX-API-DMAC7.html)
CN (1) CN116056710A (cg-RX-API-DMAC7.html)
AU (1) AU2021332350A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192776A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022047083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
FI3641771T3 (fi) 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092256B1 (en) * 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
DK4001311T3 (da) * 2014-07-09 2026-02-02 Birdie Biopharmaceuticals Inc Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
FI3641771T3 (fi) * 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
IL270253B1 (en) Stable formulations of PROGRAMMED DEATH RECEPTOR 1 (PD–1) antibodies and methods of using them
JP2024156992A (ja) 関節リウマチの治療
JP2019530752A (ja) がんを治療するための薬物の調製における、抗pd‐1抗体とvegfr阻害剤とを組み合わせた使用
KR102314003B1 (ko) 종양성 질병들에 대한 치료
US12403154B2 (en) Administration of sting agonist and checkpoint inhibitors
JP2020500152A5 (cg-RX-API-DMAC7.html)
JP2022531408A5 (cg-RX-API-DMAC7.html)
JP2018515493A5 (cg-RX-API-DMAC7.html)
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
CN114746117A (zh) 抗dll3药剂的给药方案
TW202033188A (zh) 藉由免疫檢查點阻礙藥與folfirinox療法之併用的癌症治療
EP3463453A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
JP2019519584A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
CN105813637A (zh) 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
JP2022513029A5 (cg-RX-API-DMAC7.html)
ES2935265T3 (es) Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2017515843A (ja) 抗egfr治療薬の投与量および投与
WO2022107027A1 (en) Administration of sting agonist, checkpoint inhibitors, and radiation
WO2017176565A1 (en) Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
US20240207199A1 (en) Fluorocarbon compositions and methods for enhancing immunotherapy
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
JP2025526402A5 (cg-RX-API-DMAC7.html)